Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5346 in elevated Lipoprotein(a) with high cardiovascular risk
NCT06816264Phase 2Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-7262 in hyperlipidemia, sponsored by Shandong Suncadia Medicine Co., Ltd.. Started Feb 2025; status: completed.
02
Drugs
MK-7262
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06816264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816264.